Skip to main content
Contact Us
Subscribe
E-Edition
86°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Atara Biotherapeutics, Inc.
< Previous
1
2
3
4
Next >
Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) Wins Prix Galien International Award for Best Product for Orphan/Rare Diseases
June 21, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics Announces 1-for-25 Reverse Stock Split
June 17, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 07, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
June 05, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual Meeting
May 29, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA
May 20, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress
May 09, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 03, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 05, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress
March 28, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy
February 29, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care Conference
February 28, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis
February 14, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel® Data in The Lancet Oncology
January 31, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics Announces $15 Million Registered Direct Offering
January 08, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics to Present Recent Progress and Key Upcoming Milestones at the 42nd Annual J.P. Morgan Healthcare Conference
January 08, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 04, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics Announces Closing of Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories
December 20, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meeting
December 11, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 01, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics To Present Positive New Tab-cel® Clinical Data During Oral Session at ESMO Immuno-Oncology Annual Congress 2023
November 29, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics to Participate at the 6th Annual Evercore ISI HealthCONx Conference
November 22, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics To Participate at the Stifel Healthcare Conference
November 10, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple Sclerosis
November 08, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics Announces Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories and Third Quarter 2023 Financial Results
November 01, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 06, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics Announces Plans to Submit Tab-cel® BLA in Q2 2024 Following FDA Agreement on Comparability
September 19, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 01, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics to Participate in Cell Therapies in Autoimmune Panel Discussion at the Citi 18th Annual BioPharma Conference
August 31, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics Announces Second Quarter 2023 Financial Results and Operational Progress
August 08, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.